MeSH D006646 - langerhans-cell histiocytosis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Bristol Myers Squibb | Thalidomide | Thalidomide BMS (previously Thalidomide Celgene) | 2008-04-16 | |||
| Thalidomide | Thalomid | 2023-12-09 | 1998-07-16 | |||
| Lipomed | Thalidomide | Thalidomide Lipomed | 2022-09-19 | |||
| NATCO Pharma | Thalidomide | Thalidomide | 2023-04-27 |
Clinical Trials
Historical Success Rate
Phase 1
0%0/0
Phase 2
20%11/54
Phase 3
25%3/12
Approved: 1Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use